Fig. 3

Exogenous laminin-111 is enriched in the perivascular space in cerebral vasculature. A Representative low-magnification images of Alexa-555 labeled laminin-111 (red) and CD31 (green) in the brain at 24 h after intracerebral injection. B Quantification of vessel length calculated with laminin-111 and CD31 signals. n = 4, *p = 0.0286 by Mann–Whitney U test. C Quantification of vessel area calculated with laminin-111 and CD31 signals. n = 4, *p = 0.0286 by Mann–Whitney U test. D Quantification of laminin-111 contact. n = 4. E Quantification of laminin-111 coverage. n = 4. F Representative high-magnification image of CD31 (green), Alexa-555 labeled laminin-111 (red), and AQP4 (blue) in the brain at 24 h after intracerebral injection. White arrows indicate two sites, where spatial profiles of fluorescence intensity were performed. G, H Spatial profiles of CD31 (green), laminin-111 (red), and AQP4 (blue) along white lines crossing representative capillaries in site 1 (G) and site 2 (H) in F. I Representative high-magnification images of CD31 (green), Alexa-555 labeled laminin-111 (red), and AQP4 (blue) showing the distribution of laminin-111 along the longitudinal axis of blood vessels. White arrows indicate the vascular pattern of laminin-111 at the abluminal side of endothelial cells. Data are represented as mean ± SD